Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferrostin Plus is a hematinic combination product developed and marketed by Fidson Healthcare. It is primarily indicated for the prevention and treatment of iron-deficiency anemia and associated nutritional deficiencies, particularly during high-demand physiological states such as pregnancy, lactation, and convalescence. The formulation typically contains ferrous fumarate, which serves as a source of elemental iron for hemoglobin synthesis; folic acid, which is essential for DNA synthesis and red blood cell maturation; and cyanocobalamin (Vitamin B12), which supports erythropoiesis and neurological health. As a branded generic, it is widely utilized in the Nigerian pharmaceutical market for managing nutritional anemias.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferrous fumarate + folic acid + cyanocobalamin (Fidson Healthcare Plc).